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In this issue of Cancer Cell, Goardon et al. revise earlier conclusions regarding acute myelogenous leukemia
(AML) stem cells by demonstrating that in the majority of patients, they reside in two hierarchically related
populations most similar to normal hematopoietic progenitors. These findings have implications for thera-
peutic targeting of these cells.The cancer stem cell (CSC) model pro-
poses that many human cancers are
organized as cellular hierarchies initiated
and maintained by self-renewing CSC.
These CSC can be prospectively isolated
based on their ability to serially transplant
human cancer in immunodeficient mice.
Ultimately, this model has numerous im-
plications for both the cellular origin of
cancer and cancer therapy.
CSCs were first enriched in human
acute myelogenous leukemia (AML), an
aggressive malignancy of immature
hematopoietic cells in the bone marrow.
Experiments by John Dick and colleagues
originally demonstrated that the leukemia-
initiating activity of primary human AML
cells in immunodeficient mice was exclu-
sively contained in the CD34+CD38
subpopulation of leukemia cells (Bonnet
and Dick, 1997). As normal hematopoietic
stem cells (HSC) share the CD34+CD38
immunophenotype, it was proposed that
AML stem cells arise from HSC.
We had previously shown that HSC
reside in the Lin-CD34+CD38/loCD90+
fraction of normal bone marrow, and that
CD34+CD38+ cells contained multiple
progenitors. We tested the hypothesis
that AML CSC were in the HSC compart-
ment in patients with the t(8;21) AML1/
ETO translocation, but found that while
HSC contained the translocation and its
transcripts, this fraction was nonleuke-
mic; moreover, leukemia cells resided in
an early CD34+CD38-CD90 progenitor,
while leukemic blasts and CFU-L were
CD34+CD38+ (Miyamoto et al., 2000).
From these data and others investigating
the myeloid blast crisis phase of chronic
myelogenous leukemia (CML) (Jamiesonet al., 2004), we proposed that leukemic
progression occurred in self-renewing
clones in the HSC compartment, while
frank AML and myeloid blast crisis CML
occurred in their clonal progeny at
a non-HSC progenitor stage (Weissman,
2005).
Goardon et al. now revisit and revise
these earlier conclusions through the
investigation of a large number of primary
human AML patient samples (Goardon
et al., 2011). They found that the CD34+
cells in 80% of these cases contained
two predominant populations: one
CD38-CD90-CD45RA+ and the other
CD38+CD110+CD45RA+. Both of these
corresponded to normal hematopoietic
progenitor populations rather than HSC,
with the normal CD38CD90CD45RA+
population of unknown function and the
CD38+CD110+CD45RA+ population rep-
resenting granulocyte-monocyte progeni-
tors (GMP). Significantly, the authors
demonstrated that both of these popula-
tions fromAMLpatients possess leukemia
stem cell (LSC) activity based on their
ability to serially transplant the disease in
immunodeficient mice. These populations
were hierarchically organized, whereby
the CD38CD45RA+ cells gave rise to
the GMP-like cells, but not vice versa;
moreover, the frequency of LSC was
much higher in the CD38CD45RA+ pop-
ulation compared to the GMP-like cells.
Taken together, these results expand on
the previous view of AML LSC and estab-
lish a hierarchy of populations with
decreasing frequency of LSC.
The authors went further to
investigate the normal counterparts of
these LSC-containing populations. TheyCancer Celldemonstrate that the CD38CD45RA+
and GMP-like leukemic populations
were most like the corresponding normal
progenitor populations rather than HSC
based on microarray gene expression
analysis. They then investigated the func-
tion of the previously uncharacterized
CD38CD45RA+ population and found
that in vitro, it was able to produce granu-
locytes, monocytes/macrophages, and
lymphocytes, but not erythroid cells or
megakaryocytes. Based on these results,
it was termed a lymphoid-primedmultipo-
tential progenitor (LMPP), the first des-
cription of such a population in human
hematopoiesis. Unfortunately, as previ-
ously shown (Majeti et al., 2007), this im-
munophenotypic population failed to
engraft in xenotransplantation assays,
preventing definitive in vivo confirmation.
In total, these data establish that most
cases of CD34+ AML are primarily of
hematopoietic progenitor origin, with at
least two subpopulations containing LSC.
What accounts for the difference in LSC
frequency and potential reported by
Goardon et al. compared to the previous
publications? One possibility is the use
of different recipient mouse strains in the
xenotransplantation assay. The earlier
experiments identifying AML LSC exclu-
sively in the CD34+CD38 population
were conducted by xenotransplantation
into NOD/SCID mice, whereas the current
study used NOD/SCID/IL2Rg null mice. In
addition to lacking mature B and T
lymphocytes, the NOD/SCID/IL2Rg null
mice also lack NK cells and other im-
mune functions dependent on the IL2Rg
chain. As a result, these mice enable
engraftment more robustly than the19, January 18, 2011 ª2011 Elsevier Inc. 9
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Previewsoriginal NOD/SCID mice, which may
result in detection of LSC activity in the
CD34+CD38+ fraction.
In fact, the Bonnet lab has recently re-
ported that CD34+CD38+ leukemia cells
can exhibit AML engraftment potential in
both NOD/SCID and NOD/SCID/IL2Rg
null mice (Taussig et al., 2008). In the
case of NOD/SCID mice, they showed
that anti-CD38 antibodies inhibit engraft-
ment of CD34+CD38+ leukemia cells
through an Fc-dependent mechanism
and that when this mechanism was dis-
rupted, these cells could then engraft.
However, the situation becomes more
complicated when considering another
report from the same group investigating
LSC identity in AML harboring nucleo-
phosmin mutations where LSC activity
was identified in the CD34- fraction in
half the cases and in both CD34- and
CD34+ fractions in the others (Taussig
et al., 2010). Ultimately, additional xeno-
transplantation experiments will be
needed to investigate and clarify the
identity of LSC in specific AML subtypes.
The results reported by Goardon et al.
(2011) implicate normal hematopoietic
progenitors, LMPP, and/or GMP as the
cell of origin for AML LSC in the majority
of cases. A number of investigations of
specific rare myeloid leukemia subtypes
have hinted at a progenitor origin for
LSC. For example, during myeloid blast
crisis CML, GMP-like cells exhibit
features of LSC (Jamieson et al., 2004).
Additionally, a number of investigators
have reported LSC activity in progenitor
populations in mouse models of MLL-
induced AML (Krivtsov et al., 2006).
One of the most important implications
of a progenitor phenotype for AML LSC
relates to the critical stem cell property
of self-renewal. Since self-renewal is not
a property of normal hematopoietic10 Cancer Cell 19, January 18, 2011 ª2011 Eprogenitors, being restricted to HSC, the
acquisition of self-renewal ability in AML
LSC is an aberrant event resulting from
genetic and/or epigenetic changes. The
identification of such events should yield
novel candidate therapeutic targets, and
analyses of the gene expression data
reported by Goardon et al. (2011) would
be a first step toward the identification of
these LSC-specific genes and pathways.
The most significant implication of the
leukemia stem cell model is that in order
to eradicate the leukemia and cure the
patient, all LSC must be eliminated.
Development of novel methods to target
LSC requires careful isolation and investi-
gation of these cells. We recently demon-
strated that both LSC and their progeny
expressed CD47 and were eliminated
with blocking anti-CD47 antibodies
(Majeti et al., 2009). Moreover, we
recently reported that high levels of an
LSC gene expression signature were
associated with worse clinical outcomes
in several independent patient cohorts,
suggesting that the CSC model is clini-
cally relevant for AML (Gentles et al.,
2010).
The work reported by Goardon et al. is
an essential step forward, but leaves
several critical questions unanswered.
First, in both the LMPP-like and GMP-
like leukemic fractions, limiting dilution
analysis indicates that LSC activity
requires transplantation of many cells.
Do LSC compose a very small fraction of
these populations, and/or must subsets
of these stem cells interact to support
leukemia growth in vivo? Are there better
surface markers aside from CD34 and
CD38 that can be used to isolate these
cells to much higher purity? Will surface
markers alone be sufficient to isolate
pure LSC? Second, the LSC hierarchy
reported here does not apply to all AMLlsevier Inc.cases. Can an LSC hierarchy be identified
in the other cases?Will the identity of LSC
vary among the known molecular and
cytogenetic subtypes of AML? Finally,
can methods be developed to track LSC
during the course of therapy to provide
guidance regarding therapy selection
and/or intensification? Most significantly,
will eradication of LSC ultimately prove
to be curative?REFERENCES
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